Nature Reviews Drug Discovery

Nature Reviews Drug Discovery is a premier monthly journal published by Springer Nature, holding the distinguished ISSN 1474-1776. With an exceptional 2026 Impact Factor of 91.200, it is ranked in the top JCR Quartile (Q1), solidifying its position as the highest-impact journal dedicated exclusively to drug discovery and development. The journal’s scope encompasses the entire translational pipeline, from early target identification and lead optimization through to clinical trial design, regulatory science, and market access. It covers a broad range of therapeutic areas, including oncology, neurology, immunology, infectious diseases, and cardiovascular medicine, with particular emphasis on emerging modalities such as gene editing, antibody-drug conjugates, and artificial intelligence in drug design. Article types are predominantly authoritative Reviews and Perspectives, complemented by concise News & Analysis pieces, Research Highlights, and expert Commentaries that provide critical context on breakthrough studies and policy shifts. The journal does not publish primary research articles, instead focusing on synthesizing and critically evaluating the most significant advances in the field. Its target audience includes academic researchers, pharmaceutical and biotechnology industry scientists, clinical development professionals, and regulatory and investment decision-makers who require authoritative, forward-looking insights. Notable features include rigorous peer review by subject-matter experts and a subscription-based model (not open access), ensuring high selectivity and editorial integrity. As the leading review journal in pharmacology and pharmacy, its Q1 standing and impact factor reflect unparalleled influence, making it an essential resource for staying abreast of transformative trends and strategic directions in drug discovery.